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Abstract
Introduction: We investigated early systemic sclerosis (SSc) (that is, Raynaud’s phenomenon with SSc marker
autoantibodies and/or typical capillaroscopic findings and no manifestations other than puffy fingers or arthritis)
versus undifferentiated connective tissue disease (UCTD) to identify predictors of short-term disease evolution.
Methods: Thirty-nine early SSc and 37 UCTD patients were investigated. At baseline, all patients underwent clinical
evaluation, B-mode echocardiography, lung function tests and esophageal manometry to detect preclinical
alterations of internal organs, and were re-assessed every year. Twenty-one early SSc and 24 UCTD patients, and 25
controls were also investigated for serum endothelial, T-cell and fibroblast activation markers.
Results: At baseline, 48.7% of early SSc and 37.8% of UCTD patients had at least one preclinical functional
alteration (P > 0.05). Ninety-two percent of early SSc patients developed manifestations consistent with definite SSc
(that is, skin sclerosis, digital ulcers/scars, two or more teleangectasias, clinically visible nailfold capillaries, cutaneous
calcinosis, X-ray bibasilar lung fibrosis, X-ray esophageal dysmotility, ECG signs of myocardial fibrosis and laboratory
signs of renal crisis) within five years versus 17.1% of UCTD patients (X2 = 12.26; P = 0.0005). Avascular areas (HR =
4.39 95% CI 1.18 to 16.3; P = 0.02), increased levels of soluble IL-2 receptor alpha (HR = 4.39; 95% CI 1.03 to 18.6;
P = 0.03), and of procollagen III aminopropeptide predicted disease evolution (HR = 4.55; 95% CI 1.18 to 17;
P = 0.04).
Conclusion: Most early SSc but only a few UCTD patients progress to definite SSc within a short-term follow-up.
Measurement of circulating markers of T-cell and fibroblast activation might serve to identify early SSc patients
who are more likely to develop features of definite SSc.
Introduction
Raynaud’s phenomenon (RP), which occurs in more than
95% of patients affected by systemic sclerosis (SSc), is the
most frequent onset manifestation of the disease [1]. The
identification of patients with secondary RP, who experi-
ence it as the first symptom/sign of SSc or of any other
autoimmune systemic rheumatic disease, has long been
recognized as a challenge for both the prevention and
early treatment of such disorders [2]. Various attempts
have been made to address this issue. Fine et al. [3] desig-
nated “prescleroderma” any condition characterized by RP,
digital ischemic changes and SSc marker autoantibodies
and/or capillaroscopic findings typical of the scleroderma
pattern. Subsequently, LeRoy and Medsger [4] proposed
that a condition characterized by RP and either marker
autoantibodies or typical capillaroscopic findings be desig-
nated “limited” SSc to foster the inclusion of patients not
meeting the American College of Rheumatology (ACR)
SSc criteria [5] in clinical studies. A few years ago, Koenig
et al. [6] validated the criteria proposed by LeRoy and
Medsger [4] in a large prospective study, and found that
RP patients with SSc marker autoantibodies and/or typical
SSc capillaroscopic findings and no manifestation other
than puffy fingers and/or arthritis, who will be referred to
as early SSc patients in the present paper, developed
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definite SSc in 47%, 69% and 79% of the cases within 5, 10
and 15 years, respectively, from the onset of RP. Here we
describe the evolution of the disease in patients with early
SSc during a short-term follow-up. Specifically, we looked
for baseline factors predictive of the development of
further SSc manifestations in early SSc patients. To our
knowledge, this topic has not been explored previously.
Materials and methods
All patients admitted to the Rheumatology Unit of the
Second University of Naples for a suspected secondary
RP from 1 November 2000 to 31 October 2010 were con-
sidered eligible for the study if they fulfilled LeRoy and
Medsger’s criteria [7] for RP, that is, bilateral, episodic
bi- or triphasic color changes of fingers (pallor followed
by dusky blueness and/or redness) induced by a cold
challenge. Patients who met the ACR criteria for the clas-
sification of SSc [4] or any other connective tissue disease
were excluded from the study, as were patients displaying
any feature consistent with definite SSc [6], that is, skin
sclerosis, digital ulcers/scars, two or more teleangectasias,
clinically visible nailfold capillaries, cutaneous calcinosis,
X-ray bibasilar lung fibrosis, X-ray esophageal dysmoti-
lity, ECG signs of myocardial fibrosis (cardiac blocks, Q
waves), blood tests (serum creatinine) indicative of pre-
vious scleroderma renal crisis.
After giving informed written consent, according to
standard clinical practice and to ensure a correct classifica-
tion, the selected RP patients underwent: a detailed history
and physical examination, to identify any of the previously
listed clinical signs that excluded enrolment in the study,
puffy fingers, and present or previous arthritis; routine
laboratory investigations, devoted to exclude comorbidities
and not relevant to the definition of the disease subset
(that is, early SSc, definite SSc, UCTD), including blood
cell count, urinalysis, blood urea nitrogen (BUN), serum
creatinine, alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), erythrosedimentation rate (ESR),
serum protein electrophoresis with the evaluation of gam-
maglobulin concentration, serum C3 and C4 concentra-
tion; nailfold videocapillaroscopy (NVC) using an optical
probe videocapillaroscope equipped with a ×200 magnifi-
cation contact lens and connected to image analysis soft-
ware (Videocap, DS MediGroup, Milan, Italy). The
nailfold of the second, third, fourth and fifth finger was
examined bilaterally in each patient. Four consecutive
fields extending over 1 mm in the middle of the nailfold
were studied per finger. The procedure was carried out by
a physician (MI) experienced in NVC [8-10]; an autoanti-
body screening and profiling of sera collected at the first
visit, performed as previously described [11], including
antinuclear antibodies (ANA), SSc and other connective
tissue disease marker autoantibodies, namely anti-Scl-70,
anticentromere (ACA), anti-RNA polymerase III, anti-
fibrillarin, anti-PmScl, anti-Th/To, anti-SSA, anti-SSB,
anti-Sm, anti-Jo1, anti-U1RNP and anti-dsDNA antibo-
dies; chest X-ray, barium esophageal X-ray and ECG to
identify patients not eligible for the study because of find-
ings consistent with lung, esophageal or cardiac SSc invol-
vement as assessed by routine examinations and current
treatment. Thus, patients satisfying the Koenig et al.
criteria for early SSc [6], that is, RP plus either SSc marker
autoantibodies and/or megacapillaries or avascular areas
and no manifestation other than puffy fingers and/or
arthritis, were enrolled in the study. In addition, patients
who met the criteria for undifferentiated connective tissue
disease (UCTD) (ANA positivity, but no SSc marker or
any other connective tissue disease autoantibody, no scler-
oderma videocapillaroscopic findings or any clinical mani-
festation pathognomonic of any other connective tissue
disease) [12,13], were also enrolled in the study.
At baseline, all patients underwent B-mode echocardio-
graphy, lung function tests, and esophageal manometry.
The detection of diastolic abnormalities at B-mode echo-
cardiography, indicated by an inverted ratio between
early (E)/late (atrial = A) ventricular filling velocity (E/A
ratio < 1), in the absence of arterial hypertension, coron-
ary artery disease and other symptoms/signs of cardiac
disease, was regarded as early scleroderma heart involve-
ment [14]. The detection of a diffusing lung capacity for
carbon monoxide (DLCO) or a forced vital capacity
(FVC) <80% of the predicted values in the absence of a
smoking habit and/or obstructive lung disease at lung
function study was regarded as SSc lung involvement
[15,16]. The detection of a basal low esophageal sphincter
(LES) pressure <15 mmHg, with or without impaired
peristalsis, at esophageal manometry was regarded as
early SSc esophageal involvement [8].
Lastly, 45 out of the enrolled 76 patients (21 early SSc
and 24 UCTD patients) and 25 controls, matched for sex
and age and affected with osteoarthritis or primary fibro-
myalgia syndrome, were investigated for serum endothe-
lial, T-cell and fibroblast activation markers, namely
soluble E-selectin (sE-selectin); soluble IL-2 receptor
alpha (sIL-2Ra); carboxyterminal telopeptide of type I
collagen (ICTP), and aminoterminal propeptide of type
III collagen (PIIINP). SIL-2Ra and sE-selectin concentra-
tions were measured by a multiplex suspension immu-
noassay. The assay was based on the use of polystyrene
spectrally encoded beads of 5 to 6 μm diameter as the
solid support. Each bead was coupled with a capture anti-
body specific to the analyte of interest. A first incubation
step allowed the binding of the analyte from the test sam-
ple to the solid support, then the complex bead-capture
antibody-analyte was challenged with a biotinylated
detection antibody. Finally, a streptavidin-phycoerythrin
conjugate, the reporter molecule, was added to the sys-
tem to complete the reaction on the surface of each bead,
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thus labeling the analytes (either sIL-2Ra or sE-selectin).
The assay was read with a double laser-based instrument
(Luminex 200, Luminex Corporation, Austin, Texas,
USA), which identifies each bead by a distinct spectral
region and quantifies the concentration of the bound
analyte (pg/ml) by analyzing the fluorescence intensity of
the streptavidin-phycoerythrin conjugate. Capture and
detection antibodies directed against sIL-2Ra and sE-
selectin were both originated in mice. All reagents for
this assay were provided by Merk Millipore, Billerica,
MA, USA. ICTP and PIIINP concentrations were mea-
sured by a conventional competitive radio-immunoassay
(RIA) and expressed as μg/l, using the UniQ kits by
Orion Diagnostica, Espoo, Finland. Again, none of the
investigated activation markers contributed to the defini-
tion of the disease subset (that is, early SSc, definite SSc,
UCTD).
Each patient was re-evaluated every six months for
symptoms/signs of SSc or any other connective tissue
disease, and underwent yearly ECG, chest and esopha-
geal X-ray, and lung function tests. The follow-up status
was assessed in December 2011.
The study protocol was reviewed and approved by the
local Ethics Committee.
Statistics
GraphPad Prism 5.0 (GraphPad Software Inc., San Diego,
California, U.S.A.) and MedCalc 11.3 (MedCalc Software
bvba, Mariakerke, Belgium) for Windows software were
used for statistical analyses. Continuous data were
expressed as mean ± SD and median with range, and
were compared by Student’s t-test or Mann-Whitney U
test as appropriate. Categorical data were analysed by
Fisher’s exact test. Kaplan-Meier curves were used to
describe the cumulative rates of SSc manifestations over
time in the subgroups of patients, and the log-rank test
was applied to analyse differences. Risk prediction was
assessed by univariate and multivariate logistic regression
analysis. Receiver-operating characteristic (ROC) curve
analysis was performed to identify the cut-off values of
both activation markers predicting the evolution of early
SSc to definite SSc and their respective sensitivity and
specificity. Statistical significance was expressed by a
P-value < 0.05.
Results
From 1 November 2000 to 31 October 2010, 76 patients
with RP who fulfilled the entry criteria were admitted to
the outpatient clinic. The cohort consisted of 74 women
and 2 men, aged from 17 to 73 years (median 41 years),
with a disease duration from RP onset ranging from 0.5
to 30 years, (median 3.5 years). Thirty-nine (51.3%) of
them fulfilled the criteria for early SSc and 37 (48.7%)
for UCTD.
Table 1 shows the main epidemiologic, clinical, labora-
tory and capillaroscopic features of the 39 early SSc and
37 UCTD patients. The two groups were similar in terms
of age, sex, RP duration, ANA positivity, prevalence of
abnormal routine immune-inflammatory parameters and
smoking habit. By definition, serum SSc-marker autoanti-
bodies (36/39 (92.3%) vs 0/37; P < 0.0001) and a capil-
laroscopic scleroderma pattern (23/39 (59%) vs 0/37; P <
0.0001) were detected only in early SSc patients. ANA
titers ranged from 1:80 to 1:5,120 (median 1:640) in both
groups. Arthritis was found only in UCTD patients (4/37
(10.8%) vs 0/39) (P = 0.05). Interestingly, in the early SSc
group, the two most frequent autoantibody specificities
discriminated patients with a significantly different dis-
ease duration; as expected, the ACA group (n = 26) had a
median disease duration of five years (range 1 to 24),
whereas the anti-Scl-70 group (n = 8) of 1.5 years (range
0.5 to 3) (P = 0.007). Disease duration was one year in
the patient positive to anti-Th/To and anti-U1-RNP, and
one, six and seven years in the three patients with no
marker autoantibodies. Neither the prevalence of the
capillaroscopic scleroderma pattern nor avascular areas
was related to an autoantibody pattern.
Table 2 shows the functional heart, lung and esopha-
geal abnormalities detected at enrolment. An E/A ratio
<1 was detected in 9/31 (29%) early SSc and in 3/26
(11.5%) UCTD patients, but might be due to confounding
factors, such as age and hypertension in 7/9 and 2/3 of
these patients, respectively. A DLCO <80% of the pre-
dicted value was found in 11/39 (28.2%) early SSc and
10/37 (27%) UCTD patients. A reduced basal LES pres-
sure was found in 11/36 (30.6%) early SSc and 4/27
(14.8%) UCTD patients. Therefore, these investigations
did not differ significantly between the two groups. How-
ever, when considering a DLCO <70% of the predicted
value, the cumulative prevalence of any preclinical func-
tional alteration was 18/39 (46.2%) in early SSc and 9/37
(24.3%) in UCTD patients (P = 0.057). These results indi-
cate that preclinical, functional alterations of heart, lung
and esophagus can be seen both in patients with strictly
defined early SSc and in patients with UCTD.
Table 3 reports the levels of circulating markers of
endothelial, T-cell and fibroblast activation detected in the
two groups of patients and controls. Median E-selectin
levels were higher in patients with UCTD (0.87 pg/ml vs
0.732 pg/ml in early SSc, P < 0.05; vs 0.806 pg/ml in con-
trols, P = 0.07). Median ICTP levels were higher in
patients with early SSc (3.998 μg/l vs 2.86 μg/l in UCTD
and 3.21 μg/l in controls, P < 0.05 for both). A value
exceeding the 95% percentile of those recorded in controls
was found in 6/21 (28.6%) patients with early SSc and in
0/24 patients with UCTD as regards ICTP (P = 0.007); in
5/21 (23.8%) patients with early SSc and in 2/24 (8.3%)
patients with UCTD as regards PIIINP and sIL-2Ra
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(P > 0.05); and in 0/21 patients with early SSc and in 3/24
(12.5%) patients with UCTD as regards sE-selectin (P >
0.05). These results suggest that markers of fibroblast acti-
vation, as indicated by increased levels of serum ICTP or
PIIINP, are already detectable in early SSc patients and dif-
ferentiate the latter from UCTD patients (11/21 (52.4%) vs
2/24 (8.3%); P = 0.006). T-cell activation as assessed by
increased sIL-2Ra levels was detected in both early SSc
and UCTD patients, while endothelial activation, as
assessed by increased E-selectin was found only in UCTD
patients. However, the sample size was too small to draw
any definite conclusion in this regard.
Early SSc patients were monitored for between 1 and
8 years (17 patient-year; median 3 years); UCTD
patients were also monitored for between 1 and 8 years
(14 patient-year; median 2 years). Fifteen out of 39
(38.5%) early SSc and 20 out of 37 (54.1%) UCTD
patients were followed for at least five years. At Decem-
ber 2011, one patient with early SSc had died from pul-
monary thromboembolism secondary to deep vein
thrombosis; and another early SSc patient was lost to
follow-up.
After enrolment, all patients were treated with 100
mg/day acetylsalicylic acid (ASA) and calcium channel
blockers (CCB - either nifedipine 20 to 60 mg/day or
amlodipine 5 to 10 mg/day) for RP. The four UCTD
patients presenting with arthritis were also treated with
hydroxychloroquine (HCQ) 6.5 mg/kg/day.
Figure 1 shows the time-dependent onset of new man-
ifestations consistent with definite SSc [6] in patients
with early SSc and UCTD during follow-up. Nine of the
39 (23.1%) patients with early SSc developed definite
SSc at one year, 15/31 (48.4%) at two years, 17/27
(62.9%) at three years, 18/25 (72%) at four years, and
23/25 (92%) at five years from presentation. On the
other hand, 2/37 (5.4%) UCTD patients developed defi-
nite SSc at one year, and 5/29 (17.1%) at two years
(X2 = 12.26; P = 0.0005). Interestingly, no UCTD patient






Sex: F/M 38/1 36/1 ns
Age; years (median; range) 41 (17 to 73) 38 (18 to 71) ns
RP duration; years (median; range) 3 (0.5 to 24) 4 (0.5 to 30) ns
Puffy fingers 4 0 ns
Arthritis 0 4 0.05
ESR >20 mm/h 5 6 ns
Gammaglobulins >1.5 g/dl 3 2 ns
C3 <80 mg/dl or C4 <15 mg/dl 2 3 ns
ANA + 38 (97.4) 37 (100) ns
ANA titre (median, range) 1:640 1:640 ns
SSc-marker antibodies + (1:80 to 1:5,120) (1:80 to 1:5,120) < 0.0001
ACA + 36 (92.3) 0 < 0.0001
Anti-Scl-70 + 26 (66.7) 0 0.005
Anti-Th/To 8 (20.5) 0 ns
Anti-U1RNP 1 (2.6) 0 ns
1 (2.6) 0
NVC SSc pattern 23 (59) 0 < 0.0001
Megacapillaries + avascular areas 19 (48.7) 0 < 0.0001
Avascular areas or megacapillaries 4 (10.2) 0 ns
Smoking habit 17 (43.5) 13 (35.1)
All data are expressed as numbers and percentages (in brackets), except were otherwise indicated. ACA, anticentromere antibodies; ANA, antinuclear antibodies;
ESR, erythrosedimentation rate; F, female; M, male; n, number; NVC, nailfold videocapillaroscopy; RP, Raynaud’s phenomenon; SSc, systemic sclerosis; UCTD,
undifferentiated connective tissue disease
Table 2 Preclinical alterations of heart, lung and






E/A ratio <1* 2/31 (6.5) 1/26 (3.8) ns
DLCO <80% 11/39 (28.2) 10/37 (27) ns
FVC <80% 1/39 (2.6) 1/37 (2.7) ns
Basal LES pressure <15 mmHg 11/36 (30.6) 4/27 (14.8) ns
One or more functional alteration 19/39 (48.7) 14/37 (37.8) ns
*not alternatively explained. All data are expressed as numbers and
percentages (in brackets). DLCO, diffusing lung capacity for carbon monoxide;
E/A ratio <1, inverted ratio between early (E)/late (atrial = A) ventricular filling
velocity; FVC, forced vital capacity; LES, low esophageal sphincter; SSc,
systemic sclerosis; UCTD, undifferentiated connective tissue disease
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had developed additional manifestations two years after
presentation.
Table 4 shows the various manifestations of definite SSc
that developed in early SSc and UCTD patients during the
follow-up period. Specifically, digital ulcers/scars devel-
oped in 5/39 (12.8%) patients with early SSc and in 1/37
(2.7%) with UCTD; 2 or more telangectasias became
apparent in 14/39 (35.9%) patients with early SSc and in
0/37 with UCTD; skin sclerosis developed in 4/39 (10.2%)
patients with early SSc (sclerodactyly in 3 cases and skin
sclerosis proximal to the elbows in 1) and in 0/37 with
UCTD, lung fibrosis as detected by chest X-ray developed
in 2/39 (5.1%) patients with early SSc and 1/37 (2.7%) with
UCTD, esophageal dysmotility in 3/39 (7.7%) patients with
early SSc and 3/37 (8.1%) with UCTD, cardiac blocks in 2/
39 (5.1%) patients with early SSc and 0/37 with UCTD.
Therefore, considering all the above listed complications,
manifestations consistent with definite SSc developed in
30/39 (76.9%) with early SSc and 5/37 (13.5%) patients
with UCTD (P < 0.0001).
Finally, we evaluated whether the serologic, capillaro-
scopic, clinical and functional parameters were predictive
of the development of additional clinical and/or functional
alterations in patients with early SSc. The HR was signifi-
cant for PIIINP (HR = 4.55; 95% CI 1.18 to 17; P = 0.04),
sIL-2Ra (HR = 4.39; 95% CI 1.03 to 18.6; P = 0.03), and
avascular areas (HR = 4.39; 95% CI 1.18 to 16.3; P = 0.02).
No factor was associated with the development of addi-
tional manifestations in patients with UCTD.
In order to evaluate the cut-off value with higher sensi-
tivity and specificity of each activation marker potentially
useful in predicting the development of further SSc mani-
festations in the short term, we performed a ROC analysis
for each marker, but we found inconsistent results for
both sIL-2Ra (area under the observed receiver operating
curve (AUC) 0.6250) and PIIINP (AUC 0.5515), possibly









0.732 (0.35 to 1.2) 0.87 (0.32 to 1.99) # 0.806 (0.4 to 1.76)
sIL-2Ra (pg/ml)
median (range)
239 (66.7 to 1,002) 346 (14.3 to 931) 301 (17.9 to 807)
ICTP (μg/l)
median (range)
3.998 (1.88 to 10.5)*; ° 2.86 (1.17 to 4.25) 3.21 (1.39 to 5.27)
PIIINP (μg/l)
median (range)
1.491 (0.002 to 5.43) 1.66 (0.01 to 2.98) 1.65 (0.35 to 7.49)
ICTP, carboxyterminal telopeptide of type I collagen; IL-2Ra, interleukin-2 receptor alpha; PIIINP, aminoterminal propeptide of type III collagen; s, soluble; SSc,
systemic sclerosis; UCTD, undifferentiated connective tissue disease. † Affected by osteoarthritic or primary fibromyalgia syndrome. * P < 0.05 early SSc vs
controls;°P < 0.05 early SSc vs UCTD; #P < 0.05 UCTD vs early SSc (P = 0.07 vs controls)
Figure 1 Time to development of manifestations consistent with definite SSc in early SSc and UCTD patients. Percent manifestations of
definite SSc, as assessed by routine examinations: skin sclerosis, digital ulcers/scars, two or more teleangectasias, X-ray bibasilar lung fibrosis, X-
ray esophageal dysmotility, ECG signs of myocardial fibrosis. Time: five years follow-up. Curves were generated using the Kaplan-Meier method
and differences between the two groups were analysed by applying the Log-Rank test. SSc, systemic sclerosis; UCTD, undifferentiated connective
tissue disease.
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because of the low number of patients investigated for
each marker who did not develop any manifestation dur-
ing follow-up (4/21 of those evaluated).
Discussion
The aim of this study was to investigate the disease
course in patients with strictly defined early SSc com-
pared to patients with UCTD during the five years after
presentation, and to look for baseline features predictive
of further organ involvement. The results reported
herein confirm, in a larger population, our previous data
on the prevalence of preclinical organ involvement in
early SSc [11] and demonstrate that preclinical, sclero-
derma-type, functional heart or lung or esophageal
abnormalities are common both in patients with early
SSc and in patients with UCTD. Impaired left ventricu-
lar filling, as the earliest finding of SSc myocardial dis-
ease [17], and/or a reduced DLCO, as the earliest
finding of SSc pulmonary involvement [16], and/or a
reduced basal LES pressure, as the earliest detectable
SSc esophageal abnormality [18], were detected in 19/39
(48.7%) early SSc and in 14/37 (37.8%) UCTD patients
(P > 0.05). Therefore, both patients with early SSc, who
have recently been shown to be at very high risk for
developing definite SSc during a long-term observation,
that is, 10 and 15 years [6], and patients with UCTD,
who have a much lower risk of developing definite SSc,
may already have a preclinical scleroderma-like internal
organ involvement at presentation. Our results indicate
that, at presentation, patients with early SSc do not dif-
fer in any aspect from patients with UCTD. Of note,
however, a reduced basal LES pressure at enrolment was
approximately two-fold more frequently observed in
early SSc than in UCTD patients (11/36 - 30.6% versus
4/27 - 14.8%; P = 0.23). This suggests that a subclinical
scleroderma-like esophageal involvement in early SSc, as
compared to UCTD patients, could be statistically sig-
nificant in a larger cohort study.
The above findings were not entirely unexpected. In
various studies of patients with RP, lung function altera-
tions were more prevalent in, but not exclusive to,
patients with typical capillaroscopic abnormalities and/
or marker autoantibodies [19-26].
We also found that circulating markers of endothelial,
and B-cell (gammaglobulins) and T-cell (sIL-2Ra)
responses are altered in some patients with early SSc or
UCTD, whereas abnormalities in circulating markers of
fibroblast activation, namely ICTP ± PIIINP, appear to
be restricted to early SSc. However, these findings must
be interpreted with caution, due to the small number of
our test sera.
We found that patients with early SSc developed man-
ifestations consistent with definite SSc in a significantly
higher percentage than patients with UCTD (92% vs
17.1% at five years). Therefore, even preclinical internal
organ involvement does not seem to differ in patients
with early SSc with respect to those with UCTD, the
disease course is quite different. It is noteworthy that
the drugs prescribed at admission in patients from both
groups (calcium channel blockers, ASA) are not known
to influence the disease course.
We also investigated the predictive role of any para-
meter evaluated at presentation for the development of
further scleroderma-like manifestations. We did not find
any parameter predictive of further disease manifesta-
tions in patients with UCTD. Instead, the presence of
avascular areas at nailfold capillaroscopy and of
increased serum levels of PIINP and sIL-2Ra was signif-
icantly associated with an increased risk of developing
definite SSc in patients with early SSc. These results
suggest that patients with early SSc should undergo eva-
luation of fibroblast and T-cell activation markers.






1° y 2° y 3° y 4° y 5° y 1° y 2° y*
Digital ulcers/scars 4 5 5 5 5 (12.8) 0 1 (2.7)
Teleangeactasias (≥2) 7 9 10 10 14 (35.9) 0 0
Skin sclerosis 0 3 4 4 4 (10.2) 0 0




Chest X-ray bibasilar lung fibrosis 2 2 2 2 2 (5.1) 0 1 (2.7)
Esophageal dysmotility at barium X-ray 2 2 2 2 3 (7.7) 3 (8.1)
Cardiac blocks and/or Q waves 0 0 1 2 2 (5.1) 0 0
TOTAL 30 (76.9) 5 (13.5) < 0.0001
All data are expressed as numbers and percentages (in brackets). mRSS, modified Rodnan Skin Score; SSc, systemic sclerosis; UCTD, undifferentiated connective
tissue disease; y, year. † statistical difference at the end of the follow-up period; *none of the UCTD patients developed further manifestations of definite SSc
after the second year of follow-up.
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Further studies on larger cohorts are required to define
the role of these and other potential activation markers,
not assessed in our study, in the identification of
patients at risk for developing definite SSc.
We detected a higher incidence of definite SSc with
respect to Koenig et al. [6]. In fact, 47% of their patients
with early SSc and 4% of their patients with UCTD had
developed definite SSc at five years. This discrepancy
probably depends on two factors: first, 93.45% of the
patients studied by Koenig and colleagues had been
referred by primary care physicians, whereas our Unit is
a tertiary referral center; second, the prevalence of anti-
Scl-70 positivity has long been known to be much
higher in Italian (25%) [27] than in French Canadian
(9.7%) patients [10].
Taken together, our results indicate that patients with
early SSc or UCTD in whom a scleroderma-like functional
internal organ involvement has been detected should be
regarded as being affected by SSc and, therefore, challenge
the time-honoured practice of calculating the duration of
SSc starting from the first non-RP symptom. In addition,
from a clinical point of view, our data suggest that internal
organ involvement should be assessed by sensitive and
specific functional studies in patients presenting with early
SSc or UCTD in order to identify any early alteration.
Recently, researchers from the European Scleroderma
Trials and Research (EUSTAR) group proposed criteria
for the very early diagnosis of SSc (VEDOSS) [28], namely
RP, puffy fingers, marker autoantibodies and typical capil-
laroscopic alterations. In this context, based on our find-
ings, we would label “very early SSc” the 20 SSc patients
with early SSc who did not display any functional altera-
tion and “early SSc” the 19 patients with RP and any asso-
ciated functional alteration despite the absence of any
sign/symptom. We failed to identify parameters associated
with preclinical internal involvement in patients with early
SSc or UCTD. Hopefully, the VEDOSS study, which
includes a much larger number of patients, will succeed in
this task.
Conclusions
In conclusion, the results of our study should prompt
the clinician to investigate early SSc patients for precli-
nical, functional internal organ involvement and to put
them under strict surveillance.
Abbreviations
ACA: anticentromere antibodies; ACR: American College of Rheumatology;
ALT: alanine aminotransferase; ANA: antinuclear antibodies; ASA:
acetylsalicylic acid; AST: aspartate aminotransferase; AUC: area under the
observed receiver operating curve; BUN: blood urea nitrogen; CCB: calcium
channel blockers; CI: confidence interval; DLCO: diffusing lung capacity for
carbon monoxide; E/A ratio: early/(A = atrial) late ventricular filling velocity
ratio; ECG: electrocardiography; ESR: erythrosedimentaton rate; EUSTAR:
European Scleroderma Trials and Research; FVC: forced vital capacity; HCQ.
Hydroxychloroquine; HR: hazard ratio; ICTP: carboxyterminal telopeptide of
type I collagen; LES: low esophageal sphincter; NVC: nailfold
videocapillaroscopy; PIIINP: aminoterminal propeptide of type III collagen;
RIA: radio-immunoassay; ROC: receiver-operating characteristic; RP: Raynaud’s
Phenomenon; SD: standard deviation; sE-selectin: soluble E-selectin;sIL-2Ra:
soluble IL-2 receptor alpha; SSc: systemic sclerosis; UCTD: undifferentiated
connective tissue disease; VEDOSS: very early diagnosis of systemic sclerosis.
Acknowledgements
This study was supported by the Italian Foundation for Arthritis Research
(FIRA).
Author details
1Unit of Rheumatology, via Pansini 5, 80131 Naples, Italy. 2Unit of General
Surgery, via Pansini 5, 80131 Naples, Italy. 3Unit of Respiratory
Physiopathology Unit, ASL-SA1, Via Santoriello 2, 84013 Cava De’ Tirreni (SA),
Italy. 4Unit of Internal Medicine of the Second University of Napoli, via
Pansini 5, 80131 Naples, Italy.
Authors’ contributions
GV conceived, designed and coordinated the study, and drafted the
manuscript. SV performed the multiplex suspension immunoassay,
participated in performing statistical analysis, in the drafting and in the
critical revision of the manuscript. GC acquired clinical data, performed the
statistical analysis, and participated in the design of the study and in
drafting the manuscript. MI participated in the acquisition of data and
statistical analysis. VD performed the radioimmunosorbent assay and
participated in the acquisition of clinical data. DCa participated in the
acquisition of data. GD performed esophageal manometry and participated
in the design of the study. CS performed lung function tests and
participated in the design of the study. DC performed B-mode
echocardiography and participated in the design of the study. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 April 2012 Revised: 26 June 2012
Accepted: 17 August 2012 Published: 17 August 2012
References
1. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O,
Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M: Clinical risk
assessment of organ manifestations in systemic sclerosis: a report from
the EULAR Scleroderma Trials And Research group database. Ann Rheum
Dis 2007, 66:754-763.
2. Spencer-Green G: Outcomes in primary Raynaud phenomenon: a
metaanalysis of the frequency, rates, and predictors of transition to
secondary diseases. Arch Intern Med 1998, 158:595-600.
3. Fine LG, Denton CP, Black CM, Korn JH, de Cambrugge B: Systemic
sclerosis: current pathogenetic concepts and future prospects for
targeted therapy (Report of a Meeting of Physicians and Scientists,
Royal Free Hospital, School of Medicine, London). Lancet 1996,
347:1453-1458.
4. LeRoy EC, Medsger TA Jr: Criteria for the classification of early Systemic
Sclerosis. J Rheumatol 2001, 28:1573-1576.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria Committee: Preliminary
criteria for classification of systemic sclerosis (scleroderma). Arthritis
Rheum 1980, 23:581-590.
6. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G,
Goulet JR, Rich E, Grodzicky T, Raymond Y, Senécal JL: Autoantibodies and
microvascular damage are independent predictive factors for the
progression of Raynaud’s phenomenon to systemic sclerosis. A twenty-
year prospective study of 586 patients with validation of proposed
criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912.
7. LeRoy EC, Medsger TA Jr: Raynaud’s phenomenon: a proposal for
classification. Clin Exp Rheumatol 1992, 10:485-489.
8. Sebastiani M, Manfredi A, Vukatana G, Moscatelli S, Riato L, Bocci M,
Iudici M, Principato A, Mazzuca S, Del Medico P, De Angelis R, D’Amico R,
Vicini R, Colaci M, Ferri C: Predictive role of capillaroscopic skin ulcer risk
Valentini et al. Arthritis Research & Therapy 2012, 14:R188
http://arthritis-research.com/content/14/4/R188
Page 7 of 8
index in systemic sclerosis: a multicentre validation study. Ann Rheum
Dis 2012, 71:67-70.
9. Maricq HR: Widefield capillary microscopy: technique and rating scale for
abnormalities seen in scleroderma and related disorders. Arthritis Rheum
1981, 24:1159-1165.
10. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR,
Raymond Y, Senécal JL: Predicting mortality in systemic sclerosis. Analysis
of a cohort of 309 French Canadian patients with emphasis on features
at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002,
81:154-167.
11. Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A,
Cozzolino D, Del Genio G, Santoriello C: Early systemic sclerosis:
assessment of clinical and pre-clinical organ involvement in patients
with different disease features. Rheumatology (Oxford) 2011, 50:317-323.
12. Mosca M, Neri R, Bombardieri S: Undifferentiated connective tissue
diseases (UCTD): a review of the literature and a proposal for
preliminary classification criteria. Clin Exp Rheumatol 1999, 17:615-620.
13. Doria A, Mosca M, Gambari PF, Bombardieri S: Defining unclassifiable
connective tissue diseases: incomplete, undifferentiated or both? J
Rheumatol 2005, 32:3-5.
14. Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G,
Manguso F, Alagia I, Valentini G: Echocardiographic alterations in systemic
sclerosis. A longitudinal study. Semin Arthritis Rheum 2005, 34:721-727.
15. Paone C, Chiarolanza I, Cuomo G, Ruocco L, Vettori S, Menegozzo M, La
Montagna G, Valentini G: Twelve-month azathioprine as maintenance
therapy in early diffuse systemic sclerosis patients treated for 1-year
with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007,
25:613-616.
16. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA: Pulmonary
involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985,
28:759-767.
17. Nakajma K, Taki J, Kawano M, Higuchi T, Sato S, Nishijima C, Takehara K,
Tonami N: Diastolic dysfunction in patients with systemic sclerosis
detected by gated myocardial perfusion SPECT: an early sign of cardiac
involvement. J Nucl Med 2001, 42:183-188.
18. Sjogren RW: Gastrointestinal motility disorders in scleroderma. Arthritis
Rheum 1994, 37:1265-1282.
19. Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC: A prospective
study of Raynaud phenomenon and early connective tissue disease. A
five-year report. Am J Med 1982, 72:883-888.
20. Kallenberg CGM, Pastoor GW, Wouda AA, The TH: Antinuclear antibodies
in patients with Raynaud’s phenomenon: clinical significance of
anticentromere antibodies. Ann Rheum Dis 1982, 41:382-387.
21. Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP: Evolution
of primary Raynaud’s phenomenon (Raynaud’s disease) to connective
tissue disease. Arthritis Rheum 1985, 28:87-92.
22. Fitzgerald O, Hess EV, O’Connor GT, Spencer-Green G: Prospective study of
the evolution of Raynaud’s phenomenon. Am J Med 1988, 84:718-726.
23. Kallenberg CG, Wouda AA, Hoet MH, Van Venrooij WJ: Development of
connective tissue disease in patients presenting with Raynaud’s
phenomenon: a six year follow up with emphasis on the predictive
value of antinuclear antibodies as detected by immunoblotting. Ann
Rheum Dis 1988, 47:634-641.
24. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G: The
evolution of Raynaud’s phenomenon: a longterm prospective study. J
Rheumatol 1995, 22:2226-2232.
25. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter H-P, Kundi M:
Transition from primary Raynaud’s phenomenon to secondary Raynaud’s
phenomenon identified by diagnosis of an associated disease. Results of
ten years of prospective surveillance. Arthritis Rheum 2006, 54:1974-1981.
26. Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L,
Zeni S, Fantini F: A prognostic model based on nailfold capillaroscopy for
identifying Raynaud’s phenomenon patients at high risk for the
development of a scleroderma spectrum disorders. Arthritis Rheum 2008,
58:2174-2182.
27. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M: Different antibody
patterns and different prognoses in patients with scleroderma with
various extent of skin sclerosis. J Rheumatol 1986, 13:911-916.
28. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I,
Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L,
Müller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M, EUSTAR Group: Ann
Rheum Dis 2011, 70:476-481.
doi:10.1186/ar4019
Cite this article as: Valentini et al.: Early systemic sclerosis: short-term
disease evolution and factors predicting the development of new
manifestations of organ involvement. Arthritis Research & Therapy 2012
14:R188.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Valentini et al. Arthritis Research & Therapy 2012, 14:R188
http://arthritis-research.com/content/14/4/R188
Page 8 of 8
